Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging (H&NRAD-2025-01)

19 de maio de 2026 atualizado por: Caterina Giannitto, Humanitas University

p-PHOTOLARYNX- ANTHEM: Pilot Photon-Counting CT Evaluation of the Paraglottic Space and Cartilage Involvement in Laryngeal Cancer

Laryngeal cancer can affect speaking, swallowing, and breathing. Treatment selection depends on accurately defining tumor spread within the larynx, particularly invasion of the paraglottic space, thyroid cartilage, and subglottic region. Understaging may lead to insufficient treatment and recurrence, whereas overstaging may result in unnecessarily aggressive surgery and impaired quality of life.

CT and MRI are routinely used for local staging, but both have limitations. Conventional CT may have limited soft-tissue and cartilage contrast, while MRI is more time-consuming, motion-sensitive, and not feasible in all patients. Photon-counting CT (PCCT) is a new CT technology offering higher spatial resolution, improved tissue contrast, and reconstructions at different energy levels.

This study evaluates whether PCCT performed during phonation, while the patient produces a sustained sound, can improve local staging of laryngeal cancer. Phonation may better separate and display laryngeal structures, improving detection of tumor extension.

The main hypothesis is that optimized phonation PCCT reconstructions can assess tumor spread more accurately than standard CT and may approach MRI performance. Participants undergo PCCT as part of routine preoperative imaging. Images are reconstructed using different settings and reviewed by radiologists for image quality and tumor extension. When surgery is performed, imaging findings are compared with surgical and histopathological results.

The study aims to identify the most accurate PCCT reconstruction strategy to support better treatment planning in laryngeal cancer.

Visão geral do estudo

Status

Inscrevendo-se por convite

Descrição detalhada

This is a prospective, single-center observational imaging study designed to evaluate the diagnostic performance of photon-counting computed tomography (PCCT) acquired during phonation for local staging of biopsy-proven laryngeal squamous cell carcinoma.

Study Overview and Imaging Workflow

Eligible adult patients with histologically confirmed laryngeal squamous cell carcinoma referred for preoperative imaging undergo contrast-enhanced PCCT as part of routine clinical work-up. PCCT examinations are performed on a dedicated photon-counting CT system using a standardized acquisition protocol optimized for ultra-high-resolution imaging of the larynx during phonation. Imaging is acquired in the venous phase under sustained vocalization to enhance functional and morphological assessment of glottic and subglottic structures.

For each acquisition, multiple reconstructions are generated, including ultra-high-resolution virtual monoenergetic images (VMIs) at predefined energy levels and different reconstruction kernels. A 70-keV reconstruction with standard slice thickness is included as an energy-integrating detector (EID)-CT-like reference. When available, previously acquired conventional CT and/or MRI performed as part of standard care are included for comparative analysis. Surgical histopathology serves as the reference standard for local tumor extension.

Qualitative Image Assessment

Qualitative analysis is restricted to phonation acquisitions to maximize clinical relevance and reduce reader burden. Four expert head and neck radiologists independently review anonymized and randomized datasets, blinded to reconstruction parameters. For each dataset, readers assign a qualitative diagnostic quality score using a five-point Likert scale and evaluate tumor extension into the paraglottic space, thyroid cartilage (with distinction between inner cortical erosion and full-thickness invasion), and subglottic space using predefined ordinal scoring systems. Multiplanar reformations aligned with the glottic plane and axis are mandatorily assessed as part of each dataset.

Quantitative Image Assessment

Quantitative analysis is performed by two independent observers on a dedicated workstation. Standardized regions of interest (ROIs) are placed in the primary tumor, adjacent non-tumoral laryngeal tissues, subcutaneous fat (for noise estimation), and the common carotid artery (vascular reference). ROIs are defined on a representative axial slice and propagated across all reconstructions to ensure measurement consistency. Quantitative metrics include attenuation values, image noise, signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR).

Data Management and Quality Assurance

Data are collected using structured electronic case report forms (eCRFs) derived from hospital source documents. All imaging data are anonymized prior to analysis. Quality assurance procedures are based on written standard operating procedures at the sponsor site and include verification of data completeness, internal consistency checks, and cross-validation of imaging assessments with source data (radiology reports, surgical and pathology records). Access to source data is permitted for authorized personnel in accordance with Good Clinical Practice and data protection regulations.

Statistical Analysis Plan

Given the exploratory, pilot nature of the study, the planned sample size of 60 patients is based on feasibility and the need to support descriptive and comparative multi-dataset, multi-reader analyses rather than formal hypothesis testing. Quantitative variables are summarized using appropriate descriptive statistics based on data distribution. Interobserver agreement is assessed using intraclass correlation coefficients for quantitative measures and Fleiss' kappa for ordinal qualitative scores.

The effects of VMI energy level and reconstruction kernel on quantitative and qualitative outcomes are evaluated using mixed-effects models accounting for repeated measures within patients and readers. Diagnostic performance of PCCT, and where available conventional CT and MRI, is assessed using sensitivity, specificity, predictive values, and receiver operating characteristic analysis with histopathology as the reference standard. Adjustment for multiple comparisons is applied when appropriate.

Handling of Missing Data

Missing or non-evaluable data (e.g., due to severe artifacts or unavailable histopathology) are documented explicitly. Analyses are primarily conducted on available data without imputation, and sensitivity analyses may be performed to assess the impact of missing values.

Ethical and Operational Considerations

The study does not modify standard clinical management. No study-specific adverse events are anticipated. All procedures comply with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements. Written informed consent is obtained prior to participation.

Tipo de estudo

Observacional

Inscrição (Estimado)

60

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Rozzano, Itália, 20089
        • Humanitas Research Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra de Probabilidade

População do estudo

A total of sixty patients, with biopsy-proven laryngeal squamous cell carcinoma will be enrolled in the study.

Descrição

1. SELECTION CRITERIA

Inclusion Criteria

  • Adults (≥18 years)
  • Biopsy-proven laryngeal cancer squamous cell carcinoma
  • Candidate for surgical staging able to undergo PCCT

Exclusion criteria

  • Renal failure
  • Allergy to contrast medium
  • Refusal of informed consent
  • Lack of histopathologic confirmation
  • Histopathologic diagnosis of non laryngeal tumors
  • Poor image quality due to severe artifacts

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Biopsy-Proven Laryngeal Squamous Cell Carcinoma Patients
A total of sixty patients, with biopsy-proven and clinical laryngeal squamous cell carcinoma
Photon-Counting CT (PCCT) will be performed using the Siemens Healthineers NAEOTOM Alpha, the latest generation of CT technology and the first system to apply photon-counting detector technology to laryngeal imaging. Its CdTe detectors count individual photons and measure their energy, enabling true spectral imaging with ultra-high spatial resolution (voxel size down to 0.2 mm). Multi-energy maps significantly improve tissue differentiation, allowing clearer distinction between paraglottic fat, non-ossified thyroid cartilage, and tumor tissue. The technology also reduces artifacts and enhances contrast, enabling detailed evaluation of the laryngeal cartilages and paraglottic space.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Diagnostic Accuracy of Phonation Photon-Counting CT (PCCT) for Local Tumor Extension
Prazo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.

Description:

To evaluate the diagnostic accuracy of phonation PCCT in identifying paraglottic space invasion, thyroid cartilage invasion (including distinction between inner cortical erosion and full-thickness invasion), and subglottic extension, using surgical and histopathological findings as the reference standard.

From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
Identification of the Optimal PCCT Reconstruction for Local Staging
Prazo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
To identify the best-performing phonation PCCT reconstruction (defined by VMI energy level and reconstruction kernel) for each anatomical target (paraglottic space, thyroid cartilage, subglottic space), based on diagnostic accuracy relative to histopathology.
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Robustness of Local Staging Across PCCT Reconstructions
Prazo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
To assess variability in local staging classification (paraglottic space invasion, cartilage involvement, subglottic extension) across different phonation PCCT reconstructions, including staging upgrades or downgrades between datasets.
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
Interobserver Agreement for Qualitative and Staging Assessments
Prazo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.

To evaluate interobserver reproducibility among readers for qualitative diagnostic quality scores and ordinal staging assessments of paraglottic space invasion, cartilage involvement, and subglottic extension.

.

From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
Tumor attenuation
Prazo: At baseline imaging, before surgery.
Mean attenuation measured in Hounsfield Units (HU) within tumor regions of interest.
At baseline imaging, before surgery.
Image noise
Prazo: At baseline imaging, before surgery.
Image noise defined as the standard deviation of attenuation measured in a homogeneous region (e.g., subcutaneous fat).
At baseline imaging, before surgery.
Signal-to-noise ratio (SNR)
Prazo: At baseline imaging, before surgery.
Signal-to-noise ratio calculated as mean tumor attenuation divided by image noise.
At baseline imaging, before surgery.
Contrast-to-noise ratio (CNR)
Prazo: At baseline imaging, before surgery.
Contrast-to-noise ratio calculated as the difference in attenuation between tumor and reference tissue divided by image noise.
At baseline imaging, before surgery.
CT dose index volume (CTDIvol)
Prazo: At baseline imaging, before surgery.
Volume CT dose index measured in milligray (mGy)
At baseline imaging, before surgery.
Dose-length product (DLP)
Prazo: At baseline imaging, before surgery.
Dose-length product measured in milligray-centimeters (mGy·cm).
At baseline imaging, before surgery.
Effective dose
Prazo: At baseline imaging, before surgery.
Estimated effective radiation dose expressed in millisieverts (mSv).
At baseline imaging, before surgery.
Comparison of PCCT with Conventional CT and MRI
Prazo: From completion of phonation PCCT imaging to completion of multimodality image review and histopathological correlation, assessed up to 12 weeks.
To compare the diagnostic performance of phonation PCCT with conventional energy-integrating detector CT and MRI, when available, using histopathology as the reference standard.
From completion of phonation PCCT imaging to completion of multimodality image review and histopathological correlation, assessed up to 12 weeks.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

16 de maio de 2025

Conclusão Primária (Estimado)

31 de maio de 2026

Conclusão do estudo (Estimado)

31 de maio de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

27 de dezembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de maio de 2026

Primeira postagem (Real)

22 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

At the time of registration, no final decision has been made regarding sharing of individual participant data. Any future data sharing would be subject to ethical approval, data protection regulations, and appropriate data use agreements.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever